The study met its primary endpoint in enhancing event-free survival over 12 months when compared to historical control groups.

A recent study uncovers how drug-resistant cancer cells induce changes in the tumor microenvironment. This phenomenon ...

Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at London’s Francis Crick ...

A lung cancer drug already available on the NHS has been proven to cut bladder cancer deaths and reduce the risk of the ...

Scientists from the Francis Crick Institute, UCL, UCLH and Personalis have found that a test to detect circulating tumor DNA ...

Scientists from the Francis Crick Institute, UCL, UCLH and Personalis have found that a test to detect circulating tumour DNA can predict lung cancer outcome in a Cancer Research UK-funded study.

Drug resistance poses a significant challenge to the success of cancer treatments. A new study reveals the mechanisms behind its development and ...

Personalis (PSNL) published new results from their TRACERx lung cancer study in Nature Medicine. In this study, co-authors Black and Bartha et ...

Ultrasensitive ctDNA detection with NeXT Personal shows 81% sensitivity in early-stage lung adenocarcinoma, improving ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

By Dr. Sanchari Sinha Dutta, Ph.D. New research uncovers how distinct molecular profiles and immune signatures in metastatic ...